SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant discussion following reports that Nvidia has paused evaluating its 18A chipmaking process, a crucial element of Intel's revitalized foundry strategy. However, much of the community is highly skeptical, calling the news old or manipulative, and arguing that 18A was primarily for internal use while future external foundry deals, potentially including Nvidia, are centered on the more advanced 14A node. Many investors express frustration over perceived short-term price suppression, yet maintain long-term confidence in Intel's competitive positioning.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending on high anticipation for an imminent FDA approval decision for its drug Narsoplimab, targeting a deadly disease with no approved treatments. The community is buzzing with speculation around a potential "Christmas miracle" approval, fueled by the company's recent strategic partnership with Novo Nordisk and strong clinical data, anticipating a significant short squeeze and a re-rating of the stock's value despite past regulatory hurdles.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending with high excitement following the successful orbital deployment of its BlueBird 6 satellite, a pivotal step towards delivering 5G connectivity directly to standard smartphones globally. The community views this milestone as a validation of ASTS's direct-to-device vision and a significant catalyst for future growth, generating widespread bullish sentiment and discussions about its long-term potential in the space sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant positive momentum, driven by its upcoming inclusion in the S&P MidCap 400 index, effective early next year. The community views this as a major catalyst for structural demand, anticipating increased institutional buying, enhanced liquidity, and greater visibility for the Agentic AI and automation leader.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is surging to new all-time highs, driven by intensifying industrial demand from rapidly expanding sectors like AI data centers, EVs, and solar, alongside significant global supply concerns. The rally is further fueled by China's impending export restrictions on silver, with market participants eagerly discussing a potential 'silver squeeze' and a fundamental re-evaluation of its value, though some anticipate a near-term correction after its rapid ascent.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is a major talking point as Sanofi announced its acquisition for $15.50 per share, valuing the company at $2.2 billion and representing a substantial premium. This move integrates Dynavax's marketed adult Hepatitis B vaccine, its shingles candidate, and a recently licensed oral COVID-19 vaccine program into Sanofi's global immunization portfolio. While many long-term shareholders are relieved to see a resolution, a significant portion of the community feels the acquisition price undervalues the company's assets and growth prospects.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intensified speculation for a major partnership or buyout, catalyzed by a recent acquisition in the biotech sector and heightened discussions around its undervalued protein-based vaccine platform and combination influenza/COVID candidate. Shareholders are openly frustrated with management's perceived inaction and lack of communication, echoing an activist investor's push for a strategic review to unlock value from Novavax's differentiated non-mRNA technology, especially as concerns about mRNA vaccine safety grow. This confluence of factors, coupled with high short interest, positions the company for potentially significant market movement should a transformative deal be announced.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following FDA approval of AQVESME (mitapivat) for thalassemia-associated anemia, marking the first oral medicine for this patient population. This significant regulatory milestone is driving conversations about its commercial opportunity, though community sentiment remains polarized due to prior delays in regulatory decisions and mixed clinical trial results for other indications. Discussions are ongoing regarding the drug's market potential and the broader implications for the company's trajectory amidst persistent concerns about past management decisions and overall stock performance.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is experiencing extreme volatility as a recent low-float IPO, captivating traders with its explosive price discovery. The community is debating its potential for a short squeeze against concerns about long-term fundamentals and market manipulation, positioning it as a high-risk, high-reward meme stock within the broader aerospace sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is heavily trending amid widespread speculation of an imminent buyout, fueled by recent significant insider purchases and strong financial fundamentals including growing Lupkynis sales and a robust cash position. The community is actively discussing the potential Phase 2 indications for AUR200, while many shareholders voice frustration over perceived management opacity and repeatedly call for a change in leadership to unlock further value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Nov. 13, 2025 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2223829268&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, today launched four new single stock leveraged ETFs. The funds seek to deliver twice (200%) the daily performance of a specific underlying stock. Listed on Cboe, these ETFs are the first and only strategies available for this group of growth-oriented companies.The following ETFs are expected to open for trading today:<ul><li>Tradr 2X Long BE Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=678802382&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fbex&amp;a=BEX">BEX</a>) – tracks Bloom Energy Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">BE</a>)</li><li>Tradr 2X Long CLS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=3595558559&amp;u=https%3A%2F%2Fwww.tradretfs.com%2Fcsex&amp;a=CSEX">CSEX</a>) – tracks Celestica Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">CLS</a>)</li><li>Tradr 2X Long NNE Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2182584633&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fnnex&amp;a=NNEX">NNEX</a>) – tracks NANO Nuclear Energy Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">NNE</a>)</li><li>Tradr 2X Long SNPS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=1643873749&amp;u=https%3A%2F%2Fwww.tradretfs.com%2Fsnpx&amp;a=SNPX">SNPX</a>) – tracks Synopsys Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">SNPS</a>)</li></ul>"Although they are involved in different industries, these four underlying stocks are all tied to a prevalent theme: building and supporting the AI infrastructure that will be necessary to meet America's demand for compute power," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "With this launch, the Tradr suite of leveraged ETFs now has more than fifty strategies, which is a remarkable accomplishment considering we started with just seven this April. We are grateful to our investors, the 'Tradr Tribe', and our partners for their trust and enduring support."In 2022, Tradr ETFs became the first issuer to launch leveraged ETFs on single stocks, starting with TSLQ for Tesla and NVDS for Nvidia. With today's listings, Tradr's lineup has grown to 53 leveraged ETFs representing over $2 billion in assets under management. Tradr's strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=910640517&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2223829268&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=910640517&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a> . The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000790SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

First-to-market funds seek to provide 200% long exposure on exciting growth stories

NNEX
Tradr 2X Long NNE Daily ETF

Feed

News

Sentiment

Fundamentals

Info

Latest NNEX News

NNEXTradr 2X Long NNE Daily ETF